The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

Scalp psoriasis can run the gamut from mild — with thin scales or plaques that are hardly discernible — to severe, with plaques and scales that cover the scalp, forehead, back of the neck ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable effect for a drug ...

PHILADELPHIA (WPVI) -- It stays muggy with rain chances over the next few days, but a break in the humidity arrives midweek. TONIGHT: A few spotty downpours this evening. Otherwise, it's mostly ...

Air quality alert remains in effect through 12pm Thursday Becoming partly cloudy throughout Thursday Few chances for showers and thunderstorms Friday and Saturday EXTENDED FORECAST: An isolated ...